{"id":8371,"date":"2024-10-04T10:42:02","date_gmt":"2024-10-04T15:42:02","guid":{"rendered":"https:\/\/fifarma.org\/?p=8371"},"modified":"2024-10-04T11:05:04","modified_gmt":"2024-10-04T16:05:04","slug":"declaracion-en-el-61-consejo-directivo-de-la-ops","status":"publish","type":"post","link":"https:\/\/fifarma.org\/pt\/declaracion-en-el-61-consejo-directivo-de-la-ops\/","title":{"rendered":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud"},"content":{"rendered":"

Por FIFARMA, IFPMA<\/a><\/p>\n\n\n\n

El 3 de octubre de 2024, en Washington D.C.<\/strong>, FIFARMA y IFPMA emitieron una declaraci\u00f3n en el 61\u00b0 Consejo Directivo de la OPS, centrada en el acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo, as\u00ed como otras tecnolog\u00edas de salud.<\/strong><\/p>\n\n\n\n

Durante este consejo, la OPS present\u00f3 el informe titulado \u201cAcceso y Uso Racional de Medicamentos Estrat\u00e9gicos y de Alto Costo y Otras Tecnolog\u00edas de Salud\u201d, que aborda aspectos clave como pol\u00edticas de gesti\u00f3n de tecnolog\u00edas, financiamiento, cadenas de suministro, sistemas regulatorios, innovaci\u00f3n, investigaci\u00f3n y colaboraci\u00f3n con el sector privado.<\/p>\n\n\n\n

Desde FIFARMA e IFPMA, resaltamos tres puntos fundamentales. Primero, una poblaci\u00f3n saludable es esencial para el crecimiento econ\u00f3mico y el desarrollo sostenible, lo que hace imperativa la inversi\u00f3n en los sistemas de salud. De acuerdo con el Banco Mundial, Brasil es el pa\u00eds de Am\u00e9rica Latina con mayor inversi\u00f3n en salud (9,89% del PIB), aunque a\u00fan por debajo de Portugal, que tiene la inversi\u00f3n m\u00e1s baja de Europa (10,62%). Esto enfatiza la necesidad de concebir la salud como una inversi\u00f3n y no como un gasto.<\/p>\n\n\n\n

Segundo, es indispensable contar con sistemas regulatorios maduros. El informe revela que ocho autoridades regulatorias a\u00fan requieren adoptar planes de mejora continua para ser reconocidas por la OMS. Asimismo, el 40% de los Estados Miembros no ejecutan todas las funciones regulatorias recomendadas, lo que evidencia la urgencia de fortalecer los sistemas bajo est\u00e1ndares internacionales.<\/p>\n\n\n\n

Por \u00faltimo, es crucial priorizar la investigaci\u00f3n cl\u00ednica, que no solo fortalece capacidades, sino que tambi\u00e9n genera beneficios en la salud de los pacientes, el acceso a innovaciones m\u00e9dicas, el crecimiento del conocimiento cient\u00edfico, y fomenta la inversi\u00f3n econ\u00f3mica en los pa\u00edses.<\/p>\n\n\n\n

Reconocer la salud como un pilar en la construcci\u00f3n de sociedades productivas, sostenibles y financieramente s\u00f3lidas es esencial. Invitamos a trabajar conjuntamente para desarrollar sistemas de salud m\u00e1s eficientes, que aseguren el acceso a tratamientos innovadores y mejoren la calidad de vida de todos los latinoamericanos. Estamos comprometidos con esta misi\u00f3n de construir un futuro m\u00e1s saludable y pr\u00f3spero para la regi\u00f3n.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

\n
Descarga aqu\u00ed la declaraci\u00f3n<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n

\n\n\t\t\n
    \n\t\t\t <\/ul>\n <\/div>","protected":false},"excerpt":{"rendered":"

    Durante este consejo, la OPS present\u00f3 el informe titulado \u201cAcceso y Uso Racional de Medicamentos Estrat\u00e9gicos y de Alto Costo y Otras Tecnolog\u00edas de Salud\u201d, que aborda aspectos clave como pol\u00edticas de gesti\u00f3n de tecnolog\u00edas, financiamiento, cadenas de suministro, sistemas regulatorios, innovaci\u00f3n, investigaci\u00f3n y colaboraci\u00f3n con el sector privado.<\/p>","protected":false},"author":24,"featured_media":8374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"enableOnePageScrollInPage":false,"onePageScrollCss":"","onePageScrollSpeed":1000,"onePageScrollAnimation":"easeInOutQuad","onePageScrollShowDotNavigation":true,"onePageScrollNavigation":"scaleUp","onePageScrollNavigationPosition":"right","onePageScrollNavigationHorizontal":[],"onePageScrollNavigationVertical":[],"onePageScrollNavigationSpacing":[],"onePageScrollNavigationColor":"#00ff0d","onePageScrollNavigationColorHover":"#00ff0d","onePageScrollNavigationColorActive":"#00ff0d","onePageScrollNavigationIcon":[],"onePageScrollNavigationWidth":[],"onePageScrollNavigationWidthHover":[],"onePageScrollNavigationWidthActive":[],"onePageScrollNavigationHeight":[],"onePageScrollNavigationHeightHover":[],"onePageScrollNavigationHeightActive":[],"onePageScrollNavigationBorder":[],"onePageScrollNavigationBorderHover":[],"onePageScrollNavigationBorderActive":[],"onePageScrollNavigationBorderRadius":[],"onePageScrollNavigationBorderRadiusHover":[],"onePageScrollNavigationBorderRadiusActive":[],"onePageScrollNavigationTooltipTypography":[],"onePageScrollNavigationTooltipColor":"#ffffff","onePageScrollNavigationTooltipColorHover":"","onePageScrollNavigationTooltipBgColor":"#00ff0d","onePageScrollNavigationTooltipBgColorHover":"","onePageScrollNavigationTooltipPadding":[],"onePageScrollNavigationTooltipPaddingHover":[],"onePageScrollNavigationTooltipBorderRadius":[],"onePageScrollNavigationTooltipBorderRadiusHover":[],"pageSettingsCustomCss":"","footnotes":""},"categories":[24,6,7,167,1],"tags":[98,26,60,80,49],"class_list":["post-8371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analisis","category-publicaciones","category-salud","category-salud-como-inversion","category-sin-categoria","tag-acceso","tag-america-latina","tag-fifarma","tag-pacientes","tag-salud"],"yoast_head":"\n61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud - FIFARMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/pt\/declaracion-en-el-61-consejo-directivo-de-la-ops\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud\" \/>\n<meta property=\"og:description\" content=\"Durante este consejo, la OPS present\u00f3 el informe titulado \u201cAcceso y Uso Racional de Medicamentos Estrat\u00e9gicos y de Alto Costo y Otras Tecnolog\u00edas de Salud\u201d, que aborda aspectos clave como pol\u00edticas de gesti\u00f3n de tecnolog\u00edas, financiamiento, cadenas de suministro, sistemas regulatorios, innovaci\u00f3n, investigaci\u00f3n y colaboraci\u00f3n con el sector privado.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/pt\/declaracion-en-el-61-consejo-directivo-de-la-ops\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-04T15:42:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-04T16:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"fifarmacomunicaciones\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"fifarmacomunicaciones\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/\"},\"author\":{\"name\":\"fifarmacomunicaciones\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\"},\"headline\":\"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud\",\"datePublished\":\"2024-10-04T15:42:02+00:00\",\"dateModified\":\"2024-10-04T16:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/1727902526469.jpeg\",\"keywords\":[\"acceso\",\"america latina\",\"fifarma\",\"pacientes\",\"salud\"],\"articleSection\":[\"An\u00e1lisis\",\"Publicaciones\",\"Salud\",\"Salud Como Inversi\u00f3n\",\"Sin categor\u00eda\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/\",\"name\":\"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/1727902526469.jpeg\",\"datePublished\":\"2024-10-04T15:42:02+00:00\",\"dateModified\":\"2024-10-04T16:05:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/1727902526469.jpeg\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/1727902526469.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/declaracion-en-el-61-consejo-directivo-de-la-ops\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\",\"name\":\"fifarmacomunicaciones\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"caption\":\"fifarmacomunicaciones\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud - FIFARMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/pt\/declaracion-en-el-61-consejo-directivo-de-la-ops\/","og_locale":"pt_BR","og_type":"article","og_title":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud","og_description":"Durante este consejo, la OPS present\u00f3 el informe titulado \u201cAcceso y Uso Racional de Medicamentos Estrat\u00e9gicos y de Alto Costo y Otras Tecnolog\u00edas de Salud\u201d, que aborda aspectos clave como pol\u00edticas de gesti\u00f3n de tecnolog\u00edas, financiamiento, cadenas de suministro, sistemas regulatorios, innovaci\u00f3n, investigaci\u00f3n y colaboraci\u00f3n con el sector privado.","og_url":"https:\/\/fifarma.org\/pt\/declaracion-en-el-61-consejo-directivo-de-la-ops\/","og_site_name":"FIFARMA","article_published_time":"2024-10-04T15:42:02+00:00","article_modified_time":"2024-10-04T16:05:04+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg","type":"image\/jpeg"}],"author":"fifarmacomunicaciones","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"fifarmacomunicaciones","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#article","isPartOf":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/"},"author":{"name":"fifarmacomunicaciones","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068"},"headline":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud","datePublished":"2024-10-04T15:42:02+00:00","dateModified":"2024-10-04T16:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/"},"wordCount":399,"publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"image":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg","keywords":["acceso","america latina","fifarma","pacientes","salud"],"articleSection":["An\u00e1lisis","Publicaciones","Salud","Salud Como Inversi\u00f3n","Sin categor\u00eda"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/","url":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/","name":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#primaryimage"},"image":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg","datePublished":"2024-10-04T15:42:02+00:00","dateModified":"2024-10-04T16:05:04+00:00","breadcrumb":{"@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#primaryimage","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2024\/10\/1727902526469.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/declaracion-en-el-61-consejo-directivo-de-la-ops\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"61\u00b0 Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estrat\u00e9gicos y de alto costo y otras tecnolog\u00edas de salud"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068","name":"fifarmacomunicaciones","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","caption":"fifarmacomunicaciones"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/posts\/8371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/comments?post=8371"}],"version-history":[{"count":0,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/posts\/8371\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media\/8374"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media?parent=8371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/categories?post=8371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/tags?post=8371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}